Prana Biotechnology Presents to US Investors at 34th Cowen Healthcare Conference
MELBOURNE, Monday March 3rd, 2014: Prana Biotechnology (ASX: PBT/NASDAQ:PRAN) is presenting at the 34th Annual Cowen Healthcare Conference being held in Boston USA, 3-5 March 2014.
Prana’s presentation is scheduled for Tuesday 4th March (US EST) at 8.40am. The Cowen Healthcare Conference is considered one of the largest specialist healthcare investment events in the world.
Mr Geoffrey Kempler Chairman and Chief Executive Officer will be joined by Dr Rudy Tanzi, Professor of Neurology at Harvard Medical School and Prana’s Chief Scientific Advisor to meet with institutional investors during the Conference.
The presentation will provide an overview of the mechanism of action of PBT2, the company’s lead compound under development as a treatment for Alzheimer’s and Huntington disease, details of the recent results from the Reach2HD phase 2 clinical trial and the IMAGINE trial which is due to report on Phase 2 trial results later this month.
The presentation is attached and will be webcast here.
The webcast will be available for 90 days.
